Best Practices Forum: The role of icosapent ethyl for CV risk reduction

Details & Video

Best Practices Forum: The role of icosapent ethyl for CV risk reduction banner

Program details and agenda: Select TABS on the left (computer) or SCROLL DOWN (phone)

Program Time: 60 minutes - This program is a recording of a live broadcast held on July 8, 2020
Accreditation-CME Credits: This program is not accredited. Physicians may earn self-learning credits through active steps. View more information under the Credit Eligibility tab.
Target Audience: Family physicians, cardiovascular specialists, and allied health professionals

Perspectives from family practice, diabetology, and cardiology

Overview & Objectives

Best Practices Forum: The role of icosapent ethyl for CV risk reduction

Target Audience: Family physicians, cardiovascular specialists, and allied health professionals.

Perspectives from primary care, diabetology and cardiology.

Learning Objectives:

  • To review the role of serum triglycerides as a risk marker vs. a risk factor
  • To differentiate icosapent ethyl from standard fish oils
  • To best apply the findings from the REDUCE-IT study to clinical practice



Accreditation

This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

 



Faculty

Faculty

Milan Gupta
Milan Gupta
MD, FRCPC, FCCS
Brampton, ON

David C. W. Lau
David C. W. Lau
MD, PhD, FRCPC
Calgary, AB

Richard Ward
Richard Ward
MD, CCFP, FCFP
Calgary, AB

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
Are serum triglycerides a risk factor?
Do fish oils reduce CV risk?
How does icosapent ethyl differ from fish oils?
What are the main results of the REDUCE-IT study?
What is the mechanism of benefit?
How should we use icosapent ethyl in our practices?


Sponsorship

CCRN sm

This program was developed by the Canadian Collaborative Research Network and made possible through an educational grant from HLS Therapeutics Canada.

HLS Therapeutics | Clinical Trial Statistical Analysis, Study ...



Links & Resources

Program slides:

This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization.  A PDF copy of the slides from this program are available for CCRN members from the CCRN website. Click the link below to be directed to the Resource Library.

Access CCRN Member Resource Library.